🚀 This platform speeds up gene therapy development by integrating all manufacturing steps in one streamlined process.
🔬 Additionally, 3PBIOVIAN offers a standalone Plasmid DNA (pDNA) platform. It’s designed to meet growing demands in various advanced therapeutic applications.
Introduction:
This article discusses the recent launch of two innovative platforms by CDMO 3PBIOVIAN for the manufacturing of adeno-associated virus (AAV) and plasmid DNA (pDNA), aimed at enhancing the development of gene therapies and advanced therapeutic applications.
- The AAVion® platform provides a fully integrated solution for AAV manufacturing, consolidating all critical steps from vector design to final product delivery.
- The proprietary HEK293 cell line utilized in the platform facilitates a cohesive workflow, enhancing efficiency in the manufacturing process.
- COO Pirkko Kortteinen highlights the platform’s design to achieve high titers and purities across multiple AAV serotypes without extensive optimization.
- 3PBIOVIAN also launched a standalone pDNA platform, catering to the rising demand for plasmid DNA across various therapeutic applications, including mRNA and vaccines.
- The integrated services allow for clinical labeling and direct delivery of AAV products to clinical sites, ensuring comprehensive support for clients.
Conclusion:
3PBIOVIAN’s introduction of the AAVion® and pDNA platforms represents a significant advancement in biomanufacturing capabilities. By offering a streamlined approach to AAV production and addressing the increasing need for plasmid DNA, the company positions itself as a key player in the gene therapy landscape, fostering more efficient pathways for therapeutic development.
